FDA Approves Kite’s Yescarta for Relapsed/Refractory Large B-cell Lymphoma
8 April 2022



The global biopharmaceutical company, Kite, a Gilead Company, has announced the FDA’s approval of their CAR-T cell therapy, Yescarta, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL).
Recent Stories
26 May 2022
The late-stage cell and gene
18 May 2022
Virica Biotech has announced collaboration
27 April 2022
AviadoBio has announced both the
21 April 2022
AlloVir, has announced the FDA